EAM
NBIX icon

Erste Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Erste Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.35M Hold
19,700
– – 0.03% 329
2026
Q1 		$2.54M Hold
19,700
– – 0.02% 341
2025
Q4 		$2.83M Sell
19,700
-4,100
-17% -$594K 0.02% 321
2025
Q3 		$3.34M Sell
23,800
-2,900
-11% -$393K 0.03% 298
2025
Q2 		$3.35M Buy
26,700
+2,900
+12% +$333K 0.03% 326
2025
Q1 		$2.69M Hold
23,800
– – 0.03% 275
2024
Q4 		$3.32M Hold
23,800
– – 0.04% 274
2024
Q3 		$2.74M Hold
23,800
– – 0.03% 286
2024
Q2 		$3.2M Hold
23,800
– – 0.04% 269
2024
Q1 		$3.28M Hold
23,800
– – 0.04% 264
2023
Q4 		$3.15M Hold
23,800
– – 0.05% 259
2023
Q3 		$2.74M Hold
23,800
– – 0.05% 249
2023
Q2 		$2.25M Hold
23,800
– – 0.04% 276
2023
Q1 		$2.36M Hold
23,800
– – 0.05% 277
2022
Q4 		$2.86M Hold
23,800
– – 0.06% 251
2022
Q3 		$2.45M Hold
23,800
– – 0.05% 265
2022
Q2 		$2.34M Hold
23,800
– – 0.05% 275
2022
Q1 		$2.2M Sell
23,800
-1,100
-4% -$93.2K 0.04% 284
2021
Q4 		$2.1M Hold
24,900
– – 0.04% 293
2021
Q3 		$2.35M Hold
24,900
– – 0.05% 262
2021
Q2 		$2.41M Hold
24,900
– – 0.05% 268
2021
Q1 		$2.35M Hold
24,900
– – 0.06% 252
2020
Q4 		$2.34M Sell
24,900
-14,800
-37% -$1.43M 0.06% 246
2020
Q3 		$3.88M Hold
39,700
– – 0.13% 174
2020
Q2 		$4.98M Hold
39,700
– – 0.2% 133
2020
Q1 		$3.64M Sell
39,700
-75,000
-65% -$7.34M 0.21% 125
2019
Q4 		$12.3M Buy
114,700
+18,000
+19% +$1.88M 0.55% 50
2019
Q3 		$8.72M Sell
96,700
-8,000
-8% -$747K 0.46% 58
2019
Q2 		$8.76M Sell
104,700
-1,000
-0.9% -$82.1K 0.47% 57
2019
Q1 		$9.21M Sell
105,700
-15,200
-13% -$1.27M 0.52% 43
2018
Q4 		$8.44M Buy
+120,900
New +$11.6M 0.57% 40

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Erste Asset Management's NBIX Position: Q2 2026 in Review

Erste Asset Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 19,700 shares worth $3.35M. The position accounts for 0.03% of the portfolio, ranked #329.

Erste Asset Management first reported a position in NBIX in Q4 2018 and has held it in 31 quarters since. The position peaked at $12.3M in Q4 2019. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Erste Asset Management held 19,700 shares of Neurocrine Biosciences worth $3.35M as of Q2 2026.
  • Erste Asset Management left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up 0.03% of Erste Asset Management's portfolio in Q2 2026, its #329 holding.
  • Erste Asset Management first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 31 quarters since.
  • Erste Asset Management's Neurocrine Biosciences position peaked at $12.3M in Q4 2019.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.